Goldman Sachs Asset Management (GS) is nearing a more than EUR 2B deal to buy drugmaker Synthon from BC Partners, people familiar tell the Financial Times, Ivan Levingston, Hannah Kuchler and Alexandra Heal report. BC Partners, which acquired a majority stake in the business in 2019 at an enterprise value of EUR 750M, will retain a roughly 25% stake in the group after the deal, one of the people says. TPG (TPG) and Permira were also among the bidders, the people add.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GS:
- Trump Trade: Amazon plans $1M donation to Trump’s inaugural fund
- Blackstone Reportedly Joins $3.5B Bidding War for Mitsubishi Tanabe Pharma
- Trump advisers explore pathways to shrink, eliminate bank regulators, WSJ says
- CFPB closes overdraft loophole that exempted overdraft loans from lending laws
- Goldman Sachs CFO says ‘no question’ U.S. economy has proved to be resilient